03:27:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-17 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-11-29 Extra Bolagsstämma 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
2022-10-20 08:30:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the annual Alzheimer conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco on November 29 - December 2.

The abstract, titled AC-0027875, a novel gamma-secretase modulator for the treatment of Alzheimer’s disease, will be presented at the international Alzheimer conference CTAD 2022 by Dr. Johan Sandin, CSO at AlzeCure. The other co-authors are Dr. Märta Dahlström, Dr. Maria Backlund, Veronica Lidell, Azita Rasti, Sanja Juric, Dr. Magnus Halldin, Director of Discovery DMPK & Safety assessment at AlzeCure, Dr. Pontus Forsell, Head of Discovery & Research at AlzeCure, and Dr. Gunnar Nordvall, Director of Medicinal Chemistry at AlzeCure.

The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®. The substance exhibits potent effects on the production of toxic Aβ42 and reduces levels by over 50% in vivo. GSM’s represents a promising class of Aβ42-lowering anti-amyloidogenic substances for the treatment of Alzheimer's disease. It exhibits several key properties that makes it suitable as a preventive or disease-modifying treatment for Alzheimer's disease.

“AC-0027875 rapidly reaches the brain in relevant concentrations and greatly reduces the amount of toxic Aβ42. The mechanism of Alzstatin lends itself particularly well to early, preventive treatment, and these promising data demonstrate the potent effects of our substances,” said Johan Sandin, CSO at AlzeCure Pharma.

"The goal of Alzstatin is to be able to offer a preventive and disease-modifying treatment against Alzheimer's in tablet form, and with these new data and the increased interest in the field, I look positively on the continued development work and outlicensing discussions," said Martin Jönsson, CEO of AlzeCure Pharma.

The abstract and poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).